The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies
Cells · 19.11.2025 · 14 (22) · 1813
DOI: 10.3390/cells14221813 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 19.11.2025. Verfasst von Jose-Ramon Blanco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario San Pedro, 26006 Logroño, Spain. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Microbiota. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities from Junta de Andalucia, the ISCIII-Dirección General Adjunta de Evaluación y Promoción de la Investigación—Fondo Europeo de Desarrollo Regional “A Way of Making Europe”, Instituto de…, the Instituto de Salud Carlos III.
Abstract (Originalsprache)
Cancer remains a global health challenge (18.1 million new cases in 2020), with incidence projected to reach 28 million within two decades. Ovarian cancer (OC) is the deadliest gynecologic malignancy, usually diagnosed at advanced stages and with poorly understood etiology. Emerging evidence implicates reproductive tract and gut microbiota in OC biology. Microbiota shape carcinogenesis via turnover, immunity, and metabolism; dysbiosis promotes DNA damage, inflammation, and carcinogenic metabolites, engaging multiple hallmarks of cancer. In OC, microbes may reach tumors by local ascent, translocation, or hematogenous spread, originating from vagina, upper reproductive tract, peritoneal fluid, or gut. Lactobacillus-dominant vaginal communities support mucosal integrity, whereas anaerobes disrupt barriers, increase inflammation, and correlate with OC risk; mouse models show vaginal dysbiosis accelerates tumor progression. Distinct microbial profiles in upper reproductive sites and peritoneal fluid associated with immune remodeling. Gut dysbiosis drives barrier loss, immune imbalance, and estrogen reactivation. Microbial metabolites (lipopolysaccharides, short-chain fatty acids) modulate oncogenic pathways, altering epithelial–mesenchymal transition, immune evasion, and drug resistance. Across cohorts, OC tissues and fluids show Pseudomonadota/Bacteroidota enrichment and Akkermansia depletion; fecal microbiota from OC patients accelerates tumor growth in mice, whereas Akkermansia supplementation restores antitumor immunity. Antibiotic exposure and platinum resistance associate with reduced diversity and expansion of lactate-producing taxa. Microbiome-informed interventions–diet, probiotics/postbiotics, fecal microbiota transfer, and selective antibiotics–may augment chemotherapy and immunotherapy. Overall, the microbiome is a modifiable determinant of OC risk, progression, and treatment response, warranting rigorous, standardized, multi-omics studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Universitario San Pedro, 26006 Logroño, Spain.
- Centro de Investigación Biomédica de La Rioja (CIBIR), 26006 Logroño, Spain.
- Grupo de Investigación en Cuidados y Salud (GRUPAC), de la Universidad de La Rioja, 26006 Logroño, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.
- Facultad Ciencias de la Salud, Universidad de La Rioja, La Rioja, 26006 Logroño, Spain.
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
ORCID-Profile: Jose-Ramon Blanco, Rosa Del Campo, José Avendaño-Ortiz, Mariano Laguna-Olmos, Amancio Carnero
Förderung
- the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities from Junta de Andalucia
- the ISCIII-Dirección General Adjunta de Evaluación y Promoción de la Investigación—Fondo Europeo de Desarrollo Regional “A Way of Making Europe”, Instituto de…
- the Instituto de Salud Carlos III
- NextGeneration European Union funds within the framework of the Resilience and Recovery Fund
Zitieren
APA
Blanco, J. R., Del Campo, R., Avendaño-Ortiz, J., Laguna-Olmos, M., & Carnero, A. (2025). The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies. Cells, 14(22), 1813. https://doi.org/10.3390/cells14221813
Vancouver
Blanco JR, Del Campo R, Avendaño-Ortiz J, Laguna-Olmos M, Carnero A. The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies. Cells. 2025;14(22):1813. doi:10.3390/cells14221813
BibTeX
@article{Blanco2025,
author = {Blanco, Jose-Ramon and Del Campo, Rosa and Avendaño-Ortiz, José and Laguna-Olmos, Mariano and Carnero, Amancio},
title = {The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies},
journal = {Cells},
year = {2025},
volume = {14},
number = {22},
pages = {1813},
doi = {10.3390/cells14221813}
}
EUVIMED